Neovacs raises €10 million In First French Biotech IPO In Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Neovacs floats on the Alternext beginning April 21, following tough year for the country's biotech sector.
You may also be interested in...
Neovacs Advances Anti-TNF Immunotherapy In Crohn's Patients Who Failed Biologics
Completed Phase I/II trial offered the first indication of clinical benefit with an active immunotherapy against a cytokine, the French biotech's CEO says.
Neovacs Advances Anti-TNF Immunotherapy In Crohn's Patients Who Failed Biologics
Completed Phase I/II trial offered the first indication of clinical benefit with an active immunotherapy against a cytokine, the French biotech's CEO says.
Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range
$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.